Skip to main content

Table 3 Median time to next treatment (TNT) and overall survival (OS) according to the histological subtype and treatment setting

From: Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study

  Median TNT/OS (months)
  TNT1/OS1a TNT2/OS2b TNT3/OS3c TNT4/OS4d
LMS 8.0/24.9 5.6/17.3 4.6/12.3 4.4/9.2
UPS 4.8/11.0 3.5/7.9 2.3/3.7 3.5/6.2
DLPS 4.4/11.8 5.1/8.8 2.4/6.0 3.2/8.5
SS 8.7/19.7 5.7/11.7 3.4/7.8 2.3/6.0
MPNST 4.1/12.5 2.8/7.0 3.6/8.0 3.7/5.4
  1. aCalculated from the date of first-line treatment onset
  2. bCalculated from the date of second-line treatment onset
  3. cCalculated from the date of third-line treatment onset
  4. dCalculated from the date of fourth-line treatment onset
  5. DLPS dedifferentiated liposarcomas, LMS leiomyosarcomas, MPNST malignant peripheral nerve sheath sarcomas, SS synovial sarcomas, UPS undifferentiated pleomorphic sarcomas